Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Can Barlow Flip E-Therapeutics From A Miss To A Hit?

Executive Summary

Dr Raymond Barlow, the newly appointed CEO of e-Therapeutics, is hoping he can turn the lackluster business around and reposition it as a show stealing co-star for efficient drug discovery partnering, utilizing its bioinformatics platform technology.

You may also be interested in...

Non-Inferiority 'Mistake' Hits E-Therapeutics' Depression Ambition

"Our mistake was to structure the trial as a non-inferiority to amitriptyline study," e-Therapeutics CEO Malcolm Young told Scrip. "We should have called it a 'dose-ranging' study – which is what it was." The company saw its share price plummet on Feb. 15 following top-line results from its Phase IIb trial of ETS6103 (a controlled-release formulation of the analgesic tramadol) in major depressive disorder, which failed to meet its efficacy endpoint of establishing non-inferiority when compared to amitriptyline.

Snapshot: Highlights From The First Six Months Of 2020

A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data. 

First Vaccine Approval For Janssen With Two-Dose Ebola Prophylactic

The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts